Skip to main content
. Author manuscript; available in PMC: 2020 Jul 20.
Published in final edited form as: Mult Scler. 2017 Feb 1;24(2):175–185. doi: 10.1177/1352458517695469

Table 3.

Adherence-related variables.

Measure of adherence Time frame n % Mean SD
Pharmacy records
 Proportion refills received/expected refills Past 12 days 56 0.95 0.12
 Proportion non-adherent (i.e. <80% received
 vs expected refills)
 4  7 - -
Parent-reported
 Proportion missed dosesa Past 28 days 58 0.1 0.3
 Proportion non-adherent (i.e. <80% received
 vs expected refills)
 8 14 - -
 Parental involvement in DMT use Past 2 weeks
  Remind
   0% 18 27
   25% 13 20
   50%  7 11
   75% 11 17
   100% 14 21
   Missing  3  5
  Present
   0%  9 14
   25%  8 12
   50%  7 11
   75% 15 23
   100% 24 36
   Missing  3  5
  Administer
   0% 31 47
   25%  8 12
   50%  4  6
   75%  7 11
   100% 13 20
   Missing  3  5
 Reported adherence No time frame 60  6.3 1.4
  Proportion low adherence 18 28  -  -
 Contextual factors
  Behavioral coping strategiesa  Past 4 weeks 41 51.5 11.3
  Side effectsa  Past 4 weeks 43 51.3 9.9
  Barriersa  No time frame 57 51.3 11.0
Patient-reported
 Reported adherenceb No time frame 66  5.8 1.8
  Proportion low adherenceb 27 41  -  -
 Contextual factors
  Barriersa No time frame 58 49.6 9.2
Factor scores (standardized)
 Adherence summary 49  0.0 1.0
 Parent involvement in adherence 57  0.0 1.0

SD: standard deviation; DMT: disease-modifying therapy.

a

Multiple Sclerosis Treatment Adherence Questionnaire.

b

Morisky Adherence Measure.